Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details 2)

v3.19.1
Stockholders' Equity (Details 2)
3 Months Ended
Mar. 31, 2019
$ / shares
shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Stock Options, Total Outstanding | shares 5,593,752
Stock Options, Number Exercisable | shares 4,528,900
Grant Price From 0.05 To 2.02 [Member]  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 0.05
Stock Options, Grant Price, Maximum 2.02
Stock Options, Weighted Average Exercise Price $ 0.89
Stock Options, Total Outstanding | shares 3,438,752
Stock Options, Number Exercisable | shares 3,376,876
Stock Options, Weighted Average Remaining Contractual Term 4 years 2 months 30 days
Grant Price From 2.40 To 4.60 [Member]  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 2.40
Stock Options, Grant Price, Maximum 4.60
Stock Options, Weighted Average Exercise Price $ 2.91
Stock Options, Total Outstanding | shares 1,402,000
Stock Options, Number Exercisable | shares 767,500
Stock Options, Weighted Average Remaining Contractual Term 8 years 4 months 17 days
Grant Price From 5.30 To 8.86 [Member]  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 5.30
Stock Options, Grant Price, Maximum 8.86
Stock Options, Weighted Average Exercise Price $ 6.52
Stock Options, Total Outstanding | shares 753,000
Stock Options, Number Exercisable | shares 384,524
Stock Options, Weighted Average Remaining Contractual Term 9 years 1 month 6 days